(NASDAQ: AMRX) Amneal Pharmaceuticals's forecast annual revenue growth rate of 8.46% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.64%.
Amneal Pharmaceuticals's revenue in 2026 is $3,018,760,000.On average, 6 Wall Street analysts forecast AMRX's revenue for 2026 to be $1,030,095,676,674, with the lowest AMRX revenue forecast at $981,957,424,221, and the highest AMRX revenue forecast at $1,066,592,652,390.
In 2027, AMRX is forecast to generate $1,115,360,163,045 in revenue, with the lowest revenue forecast at $1,052,119,713,744 and the highest revenue forecast at $1,163,183,786,397.